PMID- 27443345 OWN - NLM STAT- MEDLINE DCOM- 20171020 LR - 20181113 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 14 IP - 1 DP - 2016 Jul 22 TI - Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis. PG - 216 LID - 10.1186/s12967-016-0981-y [doi] LID - 216 AB - BACKGROUND: Many investigators detected the simian polyomavirus SV40 footprints in human brain tumors and neurologic diseases and recently it has been indicated that SV40 seems to be associated with multiple sclerosis (MS) disease. Interestingly, SV40 interacts with human leukocyte antigen (HLA) class I molecules for cell entry. HLA class I antigens, in particular non-classical HLA-G molecules, characterized by an immune-regulatory function, are involved in MS disease, and the levels of these molecules are modified according with the disease status. OBJECTIVE: We investigated in serum samples, from Italian patients affected by MS, other inflammatory diseases (OIND), non-inflammatory neurological diseases (NIND) and healthy subjects (HS), SV40-antibody and soluble sHLA-G and the association between SV40-prevalence and sHLA-G levels. METHODS: ELISA tests were used for SV40-antibodies detection and sHLA-G quantitation in serum samples. RESULTS: The presence of SV40 antibodies was observed in 6 % of patients affected by MS (N = 4/63), 10 % of OIND (N = 8/77) and 15 % of NIND (N = 9/59), which is suggestive of a lower prevalence in respect to HS (22 %, N = 18/83). MS patients are characterized by higher sHLA-G serum levels (13.9 +/- 0.9 ng/ml; mean +/- St. Error) in comparison with OIND (6.7 +/- 0.8 ng/ml), NIND (2.9 +/- 0.4 ng/ml) and HS (2.6 +/- 0.7 ng/ml) subjects. Interestingly, we observed an inverse correlation between SV40 antibody prevalence and sHLA-G serum levels in MS patients. CONCLUSION: The data obtained showed a low prevalence of SV40 antibodies in MS patients. These results seems to be due to a generalized status of inability to counteract SV40 infection via antibody production. In particular, we hypothesize that SV40 immune-inhibitory direct effect and the presence of high levels of the immune-inhibitory HLA-G molecules could co-operate in impairing B lymphocyte activation towards SV40 specific peptides. FAU - Rizzo, Roberta AU - Rizzo R AD - Section of Microbiology and Medical Genetics, Department of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, 44121, Ferrara, Italy. rbr@unife.it. FAU - Pietrobon, Silvia AU - Pietrobon S AD - Section of Pathology, Oncology and Experimental Biology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 44121, Ferrara, Italy. FAU - Mazzoni, Elisa AU - Mazzoni E AD - Section of Pathology, Oncology and Experimental Biology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 44121, Ferrara, Italy. FAU - Bortolotti, Daria AU - Bortolotti D AD - Section of Microbiology and Medical Genetics, Department of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, 44121, Ferrara, Italy. FAU - Martini, Fernanda AU - Martini F AD - Section of Pathology, Oncology and Experimental Biology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 44121, Ferrara, Italy. FAU - Castellazzi, Massimiliano AU - Castellazzi M AD - Section of Neurology, School of Medicine, Department of Biomedical Sciences and Specialized Surgeries, University of Ferrara, Ferrara, Italy. FAU - Casetta, Ilaria AU - Casetta I AD - Section of Neurology, School of Medicine, Department of Biomedical Sciences and Specialized Surgeries, University of Ferrara, Ferrara, Italy. FAU - Fainardi, Enrico AU - Fainardi E AD - Neuroradiology Unit, Department of Neurosciences, University Hospital of Ferrara, Ferrara, Italy. FAU - Di Luca, Dario AU - Di Luca D AD - Section of Microbiology and Medical Genetics, Department of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, 44121, Ferrara, Italy. FAU - Granieri, Enrico AU - Granieri E AD - Section of Neurology, School of Medicine, Department of Biomedical Sciences and Specialized Surgeries, University of Ferrara, Ferrara, Italy. FAU - Tognon, Mauro AU - Tognon M AD - Section of Pathology, Oncology and Experimental Biology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 44121, Ferrara, Italy. mauro.tognon@unife.it. CN - Emilia-Romagna network for Multiple Sclerosis (ERMES) study group LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160722 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - 0 (Antibodies, Viral) RN - 0 (Antigens, Viral) RN - 0 (HLA-G Antigens) RN - 0 (Immunoglobulin G) SB - IM MH - Adult MH - Aged MH - Antibodies, Viral/blood MH - Antigens, Viral/*immunology MH - Female MH - HLA-G Antigens/*blood MH - Humans MH - Immunoglobulin G/*blood MH - Inflammation/pathology MH - Male MH - Middle Aged MH - Multiple Sclerosis/*blood/*immunology MH - Simian virus 40/*immunology MH - Solubility PMC - PMC4957417 OTO - NOTNLM OT - HLA-G OT - Multiple sclerosis OT - SV40 FIR - Granieri, E IR - Granieri E FIR - Castellazzi, M IR - Castellazzi M FIR - Casetta, I IR - Casetta I FIR - Tola, M R IR - Tola MR FIR - Fainardi, E S IR - Fainardi ES FIR - Dallocchio, F IR - Dallocchio F FIR - Bellini, T IR - Bellini T FIR - Rizzo, R IR - Rizzo R FIR - Rotola, A IR - Rotola A FIR - Di Luca, D IR - Di Luca D FIR - Seraceni, S IR - Seraceni S FIR - Contini, C IR - Contini C FIR - Sabbioni, S IR - Sabbioni S FIR - Negrini, M IR - Negrini M FIR - Tognon, M IR - Tognon M FIR - Antonelli, T IR - Antonelli T FIR - Groppo, E IR - Groppo E FIR - Gentile, M IR - Gentile M FIR - Baldi, E IR - Baldi E FIR - Caniatti, M L IR - Caniatti ML FIR - Ceruti, S IR - Ceruti S FIR - Manfrinato, M R IR - Manfrinato MR FIR - Trentini, A IR - Trentini A FIR - Bortolotti, D IR - Bortolotti D FIR - Miotto, E IR - Miotto E FIR - Ferracin, M IR - Ferracin M FIR - Mazzoni, E IR - Mazzoni E FIR - Pietrobon, S IR - Pietrobon S FIR - Masini, I IR - Masini I FIR - Rotondo, J C IR - Rotondo JC FIR - Martini, F IR - Martini F FIR - Baruzzi, A IR - Baruzzi A FIR - D'Alessandro, R IR - D'Alessandro R FIR - Michelucci, R IR - Michelucci R FIR - Salvi, F IR - Salvi F FIR - Stecchi, S IR - Stecchi S FIR - Scandellari, C IR - Scandellari C FIR - Terzano, G IR - Terzano G FIR - Granella, F IR - Granella F FIR - Nichelli, P IR - Nichelli P FIR - Sola, P IR - Sola P FIR - Ferraro, D IR - Ferraro D FIR - Vitetta, F IR - Vitetta F FIR - Simone, A M IR - Simone AM FIR - Bedin, R IR - Bedin R FIR - Marcello, N IR - Marcello N FIR - Motti, L IR - Motti L FIR - Montepietra, S IR - Montepietra S FIR - Guidetti, D IR - Guidetti D FIR - Immovilli, P IR - Immovilli P FIR - Montanari, E IR - Montanari E FIR - Pesci, I IR - Pesci I FIR - Guareschi, A IR - Guareschi A FIR - Greco, G IR - Greco G FIR - Santangelo, M IR - Santangelo M FIR - Mauro, A M IR - Mauro AM FIR - Malagu, S IR - Malagu S FIR - Rasi, F IR - Rasi F FIR - Spadoni, M IR - Spadoni M FIR - Galeotti, M IR - Galeotti M FIR - Fiorani, L IR - Fiorani L FIR - Neri, W IR - Neri W FIR - Ravasio, A IR - Ravasio A FIR - Pasquinelli, M IR - Pasquinelli M FIR - Gutman, S IR - Gutman S FIR - Monaldini, C IR - Monaldini C EDAT- 2016/07/23 06:00 MHDA- 2017/10/21 06:00 PMCR- 2016/07/22 CRDT- 2016/07/23 06:00 PHST- 2016/03/29 00:00 [received] PHST- 2016/07/13 00:00 [accepted] PHST- 2016/07/23 06:00 [entrez] PHST- 2016/07/23 06:00 [pubmed] PHST- 2017/10/21 06:00 [medline] PHST- 2016/07/22 00:00 [pmc-release] AID - 10.1186/s12967-016-0981-y [pii] AID - 981 [pii] AID - 10.1186/s12967-016-0981-y [doi] PST - epublish SO - J Transl Med. 2016 Jul 22;14(1):216. doi: 10.1186/s12967-016-0981-y.